📋 Tender Overview
The contract involves entering into a non-exclusive discount agreement for pharmaceuticals containing the active ingredient Tafamidis (ATC code: N07XX08) at a strength of 20mg. This agreement will be effective from December 1, 2026, to November 30, 2028, with the possibility of contract conclusion at any time during the term (open-house model). The AOK Niedersachsen will offer discount agreements to all interested pharmaceutical companies without selection decisions, serving as a bridge between the start of generic competition and the awarding of exclusive contracts. Tafamidis 20mg
